Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;62(6):4952-4966.
doi: 10.1007/s10528-024-10680-1. Epub 2024 Feb 20.

Daturataturin A Ameliorates Psoriasis by Regulating PPAR Pathway

Zheng Wei  1 , Hongfa Zhong  2 , Shanmin Yuan  1 , Cong Chen  3
Affiliations

Daturataturin A Ameliorates Psoriasis by Regulating PPAR Pathway

Zheng Wei et al. Biochem Genet. 2024 Dec.

Abstract

Psoriasis is a kind of severe immune-mediated systemic skin disorder, becoming a worldwide public health concern. Daturataturin A (DTA), a withanolide compound, exerts excellent anti-inflammatory and anti-proliferative properties. The objective of this study is to elucidate the effect of DTA on psoriasis and its potential mechanism. We established psoriasis-like keratinocytes model by stimulating HaCaT cells with M5 cocktail cytokines including Interleukin (IL)-17A, IL-22, oncostatin M, IL-1α, and tumor necrosis factor-α (TNF-α), followed by intervention with DTA. The potential effects and mechanisms of DTA on psoriasis were evaluated in vitro. DTA was found to be able to inhibit hyperproliferation, promote apoptosis, decrease the release of pro-inflammatory cytokines, downregulate keratin expression, and improve lipid metabolism via regulating the peroxisome proliferator-activated receptor (PPAR) signaling pathway by M5 cocktail cytokines stimulation in HaCaT cells. DTA ameliorated lipid metabolism of psoriasis and exerted the potential anti-psoriasis effects by regulating PPAR pathway in vitro, suggesting that DTA may act as a new therapeutic agent for psoriasis.

Keywords: Daturataturin A; Lipid metabolism; PPAR signaling pathway; Psoriasis; Therapeutic agent.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that they have no conflict of interests. Ethical Approval: Not applicable.

Similar articles

See all similar articles

References

    1. Albanesi C, Madonna S, Gisondi P, Girolomoni G (2018) The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front Immunol 9:1549 - DOI - PubMed - PMC
    1. Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323(19):1945–1960 - DOI - PubMed
    1. Chen H, Tan H, Wan J, Zeng Y, Wang J, Wang H, Lu X (2023) PPAR-gamma signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. Pharmacol Ther 245:108391 - DOI - PubMed
    1. Cheng Y, Liu Y, Tan J, Sun Y, Guan W, Jiang P, Yang B, Kuang H (2020) Integrated serum metabolomics and network pharmacology approach to reveal the potential mechanisms of withanolides from the leaves of Datura metel L. on psoriasis. J Pharm Biomed Anal 186:113277 - DOI - PubMed
    1. Constantin C, Surcel M, Munteanu A, Neagu M (2023) Insights into nutritional strategies in psoriasis. Nutrients 15(16):3528 - DOI - PubMed - PMC

Substances

LinkOut - more resources